Watson Laboratories, Inc. ("Watson") is a U.S. generic pharmaceutical manufacturer and ANDA holder. Its corporate lineage runs through Watson Pharmaceuticals, Inc., founded in 1984 by Allen Chao and David Hsia, incorporated in 1985, taken public in 1993 (NYSE: WPI), and long headquartered in Corona, California. Watson Pharmaceuticals acquired Actavis Group in 2012 and adopted the Actavis name; after the 2015 Actavis–Allergan combination, the generics business — including Watson Laboratories — was sold to Teva Pharmaceutical Industries Ltd. in 2016. Watson Laboratories, Inc. is therefore now a Teva affiliate; the Xyrem MDL docket's corporate disclosure lists Teva Pharmaceutical Industries Ltd. as an affiliate. Note the name is also loosely used for the former Watson Pharmaceuticals parent (later Actavis, then Allergan), so entity identification matters.
Products / operations. Watson develops, manufactures and markets generic prescription medicines — bioequivalents of off-patent brands filed under ANDAs. Historically its portfolio spanned pain management/analgesics, cardiovascular, CNS, women's health and urology, with in-house modified-release and drug-delivery capability. At its 2007–2010 peak the parent marketed roughly 150–160 U.S. generic product families with several thousand employees; the parent's revenue was about $2.5B (2007). No current standalone financials are published for Watson Laboratories, Inc. as a distinct entity.
Litigation posture. This is an operating company, not an NPE: 0 plaintiff cases and 1 defendant case in the tracked data. Its appearance is defensive — and notably in antitrust, not pure patent, litigation. Historically Watson was also a defendant in Jazz's Hatch-Waxman patent suits over Xyrem (Jazz sued it in December 2014 over ANDA No. 204952, generic sodium oxybate 500 mg/mL oral solution), and it has been named in opioid and generics antitrust matters.
Notable case. In re Xyrem (Sodium Oxybate) Antitrust Litigation, No. 3:20-md-02966-RS (N.D. Cal.) — an MDL consolidated in December 2020 from class actions filed in the S.D.N.Y. and N.D. Cal. Plaintiffs (direct/indirect purchasers, end-payors and health plans) allege Jazz and generic ANDA filers including Watson entered reverse-payment/market-allocation settlements delaying generic sodium oxybate. Watson/Teva settled with Jazz in March 2018; the license allowed a Teva generic launch on or after December 31, 2025, or earlier on certain events.